Home › Companies › AKERO THERAPEUTICS INC. › 2024-2025

AKERO THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and AKERO THERAPEUTICS INC.’s Form 8-K, filed 2025-06-04 (Item 5.07 on EDGAR). Page generated 02 October 2026.

5Ballot items
255Asset managers
1,322Fund votes
2025-06-03Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore AKERO THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by AKERO THERAPEUTICS INC.

These tallies are AKERO THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AKERO THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-03
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Judy Chou, Ph.D.	46,654,444	--	--	15,405,899	5,333,604	Majority: yes
Elect Director: Tomas Heyman	28,017,151	--	--	34,043,192	5,333,604	Plurality election
The Company's stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2.	67,325,603	38,564	29,780	--	0	Majority: yes
The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 3.	60,698,263	1,199,541	162,539	--	5,333,604	Majority: yes

Source: AKERO THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-04 — read the filing on EDGAR.

How asset managers voted at the AKERO THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 255 asset managers that disclosed a AKERO THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To consider and act upon a non- binding, advisory vote to approve the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2025-06-03.

Combines 11 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 60,698,263AGAINST: 1,199,541

AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 3.”): 60,698,263 for, 1,199,541 against, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 253 asset managers below cast 99.3% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 99.1%

FOR: 99.2%AGAINST: 0.6%ABSTAIN: 0.2%NOT VOTED: 0.0%

Largest asset managers voting on “To consider and act upon a non- binding, advisory vote to approve the compensation of our named executive offi” at AKERO THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	7,954,073	621	For
T. Rowe Price	7,820,263	0	For
RTW INVESTMENTS, LP	7,419,340	0	For
Janus Henderson	6,535,723	0	For
Wellington	5,389,044	0	For
BlackRock	4,195,469	0	For
Fidelity	3,622,616	0	For
State Street	3,377,705	0	For
JANUS INVESTMENT FUND	2,139,467	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,757,957	0	For
MARSHALL WACE, LLP	1,693,805	0	For
AllianceBernstein	1,567,651	0	For
Deep Track Capital, LP	1,407,806	0	For
Charles Schwab	1,183,588	0	For
Logos Global Management LP	949,655	0	For
Redmile Group, LLC	849,715	0	For
Aberdeen	813,400	0	For
Point72	775,454	0	For
Loomis Sayles	755,143	0	For
ACAP Strategic Fund	743,040	0	For
PERCEPTIVE ADVISORS LLC	673,795	0	For
Rock Springs Capital Management LP	669,147	0	For
PICTET ASSET MANAGEMENT SA	616,469	0	For
ALKEON CAPITAL MANAGEMENT LLC	567,308	0	For
Northern Trust	535,547	0	For

Showing the 25 largest of 253 asset managers. See all 253 in the interactive database.

2. To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2028 Annual Meeting of stockholders and until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal: Judy Chou, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-03.

Combines 6 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%WITHHELD 25%

FOR: 46,654,444WITHHELD: 15,405,899

AKERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Judy Chou, Ph.D.”): 46,654,444 for, 15,405,899 withheld, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 79 asset managers below cast 100% of the shares they voted on this item FOR (18,317,301 for, 0 against).

FOR 73%ABSTAIN 27%

FOR: 18,317,301 (72.5%)ABSTAIN: 6,933,632 (27.5%)

Largest asset managers voting on “To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until” at AKERO THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	7,781,005	0	For
T. Rowe Price	0	3,360,888	Abstain
Fidelity	2,614,174	0	For
JANUS INVESTMENT FUND	2,139,467	0	For
BlackRock	1,750,114	0	For
State Street	974,743	1,097	For
ACAP Strategic Fund	0	743,040	Abstain
Charles Schwab	588,455	0	For
TIAA	415,114	0	For
AllianceBernstein	0	406,747	Abstain
Aberdeen	0	406,700	Abstain
Principal	159	304,719	Abstain
Equitable	118,844	185,900	Abstain
ALGER FUNDS	0	302,068	Abstain
Loomis Sayles	280,157	0	For
AB DISCOVERY GROWTH FUND, INC.	0	239,130	Abstain
Hartford	229,255	0	For
Advantage Advisers Xanthus Fund, L.L.C.	0	211,967	Abstain
MUTUAL FUND SERIES TRUST	200,000	0	For
Yiheng Capital Management, L.P.	176,260	0	For
Brighthouse	76,631	96,678	Abstain
Columbia Threadneedle	153,335	0	For
Dimensional	0	135,214	Abstain
QUANTITATIVE MASTER SERIES LLC	126,846	0	For
John Hancock	28,760	65,971	Abstain

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

3. To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2028 Annual Meeting of stockholders and until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal: Tomas Heyman

DIRECTOR ELECTIONSCompany result: Plurality election

Meeting held 2025-06-03.

Combines 6 wordings of this item as funds reported it.

45.1% Plurality election · of votes cast

FOR 45.1%WITHHELD 54.9%

FOR: 28,017,151WITHHELD: 34,043,192

AKERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Tomas Heyman”): 28,017,151 for, 34,043,192 withheld, per its Form 8-K filed 2025-06-04 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.

The 79 asset managers below cast 100% of the shares they voted on this item FOR (7,914,497 for, 0 against).

FOR 31%ABSTAIN 69%

FOR: 7,914,497 (31.3%)ABSTAIN: 17,336,436 (68.7%)

Largest asset managers voting on “To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until” at AKERO THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	4,122,882	3,658,123	For
T. Rowe Price	0	3,360,888	Abstain
Fidelity	1,011,588	1,602,586	Abstain
JANUS INVESTMENT FUND	2,139,467	0	For
BlackRock	109,966	1,640,148	Abstain
State Street	2,270	973,570	Abstain
ACAP Strategic Fund	0	743,040	Abstain
Charles Schwab	0	588,455	Abstain
TIAA	0	415,114	Abstain
AllianceBernstein	0	406,747	Abstain
Aberdeen	0	406,700	Abstain
Principal	0	304,878	Abstain
Equitable	0	304,744	Abstain
ALGER FUNDS	0	302,068	Abstain
Loomis Sayles	0	280,157	Abstain
AB DISCOVERY GROWTH FUND, INC.	0	239,130	Abstain
Hartford	0	229,255	Abstain
Advantage Advisers Xanthus Fund, L.L.C.	0	211,967	Abstain
MUTUAL FUND SERIES TRUST	200,000	0	For
Yiheng Capital Management, L.P.	176,260	0	For
Brighthouse	8,019	165,290	Abstain
Columbia Threadneedle	0	153,335	Abstain
Dimensional	0	135,214	Abstain
QUANTITATIVE MASTER SERIES LLC	0	126,846	Abstain
John Hancock	0	94,731	Abstain

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

4. TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2025-06-03.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 67,325,603AGAINST: 38,564

AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2.”): 67,325,603 for, 38,564 against, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 79 asset managers below cast 99.9% of the shares they voted on this item FOR (25,241,336 for, 834 against).

FOR 99.9%

FOR: 25,241,336 (100.0%)AGAINST: 834 (0.0%)ABSTAIN: 8,763 (0.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR TH” at AKERO THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	7,781,005	0	For
T. Rowe Price	3,360,888	0	For
Fidelity	2,614,174	0	For
JANUS INVESTMENT FUND	2,139,467	0	For
BlackRock	1,750,114	0	For
State Street	975,840	0	For
ACAP Strategic Fund	743,040	0	For
Charles Schwab	588,455	0	For
TIAA	415,114	0	For
AllianceBernstein	406,747	0	For
Aberdeen	406,700	0	For
Principal	304,878	0	For
Equitable	304,744	0	For
ALGER FUNDS	302,068	0	For
Loomis Sayles	280,157	0	For
AB DISCOVERY GROWTH FUND, INC.	239,130	0	For
Hartford	229,255	0	For
Advantage Advisers Xanthus Fund, L.L.C.	211,967	0	For
MUTUAL FUND SERIES TRUST	200,000	0	For
Yiheng Capital Management, L.P.	176,260	0	For
Brighthouse	164,546	8,763	For
Columbia Threadneedle	153,335	0	For
Dimensional	135,214	0	For
QUANTITATIVE MASTER SERIES LLC	126,846	0	For
John Hancock	94,731	0	For

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

5. To consider and act upon a non- binding, advisory vote to approve the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2024-06-07 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 52,835,974AGAINST: 2,548,327

AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 3.”): 52,835,974 for, 2,548,327 against, per its Form 8-K filed 2024-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 216 against).

AGAINST 100%

AGAINST: 216 (100.0%)

Largest asset managers voting on “To consider and act upon a non- binding, advisory vote to approve the compensation of our named executive offi” at AKERO THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
COLDSTREAM CAPITAL MANAGEMENT INC	0	216	0	0	Against
Echo45 Advisors LLC	0	0	0	0	--

Largest AKERO THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of AKERO THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting.

Top AKERO THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	Shares voted
1	Vanguard	7,954,694
2	T. Rowe Price	7,820,263
3	RTW INVESTMENTS, LP	7,419,340
4	Janus Henderson	6,535,723
5	Wellington	5,389,044
6	BlackRock	4,195,469
7	Fidelity	3,622,616
8	State Street	3,377,705
9	JANUS INVESTMENT FUND	2,139,467
10	GEODE CAPITAL MANAGEMENT, LLC	1,757,957

Shown as share counts, not percentages: no shares-outstanding figure has been matched to AKERO THERAPEUTICS INC. for the 2024-2025 season, so there is no denominator to divide by.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At AKERO THERAPEUTICS INC.'s shareholder meeting held 2025-06-03, in the 2024-2025 proxy season, 255 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,322 separate fund positions. On the most widely held item on that ballot — To consider and act upon a non- binding, advisory vote to approve the compensation of our named… — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: AKERO THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-04.

AKERO THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.